

TEST INFORMATION UPDATE

MIDL PCR CMV QI – (LAB 1332) TEST METHODOLOGY CHANGE

Effective Date: May 10, 2023

Effective May 10, 2023, the VUMC Molecular Infectious Disease Laboratory (MIDL) is transitioning to a polymerase chain reaction (PCR) based assay to test for congenital CMV infection by testing saliva.

Our current methodology utilizes loop-mediated isothermal amplification (LAMP technology). The MIDL currently confirms all detected results with secondary testing due to the possibility of false-positive results generated by this assay. To avoid delays in turn-around time and yield consistently reliable results, the MIDL is transitioning to a polymerase chain reaction (PCR) based assay.

TEST ORDERING: *The same order in Epic/eStar will continue to be used for the new methodology – MIDL PCR CMV QI (CMD), LAB1332*

SPECIMEN COLLECTION: *The preferred specimen collection container is an oral swab placed into 1mL of universal transport medium (UTM; red cap tube with orange liquid).*

RESULT REPORTING: *Results will continue to be reported as NOT DETECTED or DETECTED. eSTAR results will still be visible in the same location in patient's chart (Microbiology -> Virology).*